Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission: A Safety Trial in Kidney Transplant Recipients
Latest Information Update: 27 Mar 2026
At a glance
- Drugs SYN 002 (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- Acronyms RESPECT-CMV
Most Recent Events
- 27 Mar 2026 New trial record